Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
2000 1
2001 1
2005 1
2007 2
2008 2
2009 1
2010 2
2011 5
2012 4
2013 6
2014 2
2015 3
2016 4
2017 7
2018 11
2019 9
2020 13
2021 19
2022 11
2023 6
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer.
Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, Barahona P, Wilkie EE, Sullivan P, Bowen-James R, Syed M, Martincorena I, Abascal F, Sherstyuk A, Bolanos NA, Baber J, Priestley P, Dolman MEM, Fleuren EDG, Gauthier ME, Mould EVA, Gayevskiy V, Gifford AJ, Grebert-Wade D, Strong PA, Manouvrier E, Warby M, Thomas DM, Kirk J, Tucker K, O'Brien T, Alvaro F, McCowage GB, Dalla-Pozza L, Gottardo NG, Tapp H, Wood P, Khaw SL, Hansford JR, Moore AS, Norris MD, Trahair TN, Lock RB, Tyrrell V, Haber M, Marshall GM, Ziegler DS, Ekert PG, Cowley MJ. Wong M, et al. Among authors: trahair tn. Nat Med. 2020 Nov;26(11):1742-1753. doi: 10.1038/s41591-020-1072-4. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020650
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.
Mayoh C, Mao J, Xie J, Tax G, Chow SO, Cadiz R, Pazaky K, Barahona P, Ajuyah P, Trebilcock P, Malquori A, Gunther K, Avila A, Yun DY, Alfred S, Gopalakrishnan A, Kamili A, Wong M, Cowley MJ, Jessop S, Lau LMS, Trahair TN, Ziegler DS, Fletcher JI, Gifford AJ, Tsoli M, Marshall GM, Haber M, Tyrrell V, Failes TW, Arndt GM, Lock RB, Ekert PG, Dolman MEM. Mayoh C, et al. Among authors: trahair tn. Cancer Res. 2023 Aug 15;83(16):2716-2732. doi: 10.1158/0008-5472.CAN-22-3702. Cancer Res. 2023. PMID: 37523146 Free PMC article.
Precision-guided treatment in high-risk pediatric cancers.
Lau LMS, Khuong-Quang DA, Mayoh C, Wong M, Barahona P, Ajuyah P, Senapati A, Nagabushan S, Sherstyuk A, Altekoester AK, Fuentes-Bolanos NA, Yeung V, Sullivan A, Omer N, Diamond Y, Jessop S, Battaglia L, Zhukova N, Cui L, Lin A, Gifford AJ, Fleuren EDG, Dalla-Pozza L, Moore AS, Khaw SL, Eisenstat DD, Gottardo NG, Wood PJ, Tapp H, Alvaro F, McCowage G, Nicholls W, Hansford JR, Manoharan N, Kotecha RS, Mateos MK, Lock RB, Tyrrell V, Haber M, Trahair TN, Cowley MJ, Ekert PG, Marshall GM, Ziegler DS. Lau LMS, et al. Among authors: trahair tn. Nat Med. 2024 Jul;30(7):1913-1922. doi: 10.1038/s41591-024-03044-0. Epub 2024 Jun 6. Nat Med. 2024. PMID: 38844796 Free PMC article.
Mouse models of high-risk neuroblastoma.
Kamili A, Atkinson C, Trahair TN, Fletcher JI. Kamili A, et al. Among authors: trahair tn. Cancer Metastasis Rev. 2020 Mar;39(1):261-274. doi: 10.1007/s10555-020-09855-0. Cancer Metastasis Rev. 2020. PMID: 31989509 Review.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: trahair t. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
Circulating Tumor DNA in Pediatric Cancer.
Doculara L, Trahair TN, Bayat N, Lock RB. Doculara L, et al. Among authors: trahair tn. Front Mol Biosci. 2022 May 12;9:885597. doi: 10.3389/fmolb.2022.885597. eCollection 2022. Front Mol Biosci. 2022. PMID: 35647029 Free PMC article. Review.
Spinal Canal Involvement in Neuroblastoma.
Trahair T, Sorrentino S, Russell SJ, Sampaio H, Selek L, Plantaz D, Freycon C, Simon T, Kraal K, Beck-Popovic M, Haupt R, Ash S, De Bernardi B. Trahair T, et al. J Pediatr. 2017 Sep;188:294-298. doi: 10.1016/j.jpeds.2017.05.051. Epub 2017 Jun 20. J Pediatr. 2017. PMID: 28645442 Review. No abstract available.
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M, Ash S, Chan GCF, Laureys G, Beck-Popovic M, Vettenranta K, Balwierz W, Schroeder H, Owens C, Cesen M, Papadakis V, Trahair T, Schleiermacher G, Ambros P, Sorrentino S, Pearson ADJ, Ladenstein RL. Garaventa A, et al. Among authors: trahair t. J Clin Oncol. 2021 Aug 10;39(23):2552-2563. doi: 10.1200/JCO.20.03144. Epub 2021 Jun 21. J Clin Oncol. 2021. PMID: 34152804 Clinical Trial.
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
Toscan CE, McCalmont H, Ashoorzadeh A, Lin X, Fu Z, Doculara L, Kosasih HJ, Cadiz R, Zhou A, Williams S, Evans K, Khalili F, Cai R, Yeats KL, Gifford AJ, Pickford R, Mayoh C, Xie J, Henderson MJ, Trahair TN, Patterson AV, Smaill JB, de Bock CE, Lock RB. Toscan CE, et al. Among authors: trahair tn. Blood Cancer J. 2024 Nov 6;14(1):192. doi: 10.1038/s41408-024-01180-x. Blood Cancer J. 2024. PMID: 39505850 Free PMC article.
100 results